BCAM INTERNATIONAL INC
NT 10-Q, 2000-11-15
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: IMMUNOGEN INC, S-3/A, EX-23.1, 2000-11-15
Next: BCAM INTERNATIONAL INC, NT 10-Q, EX-99, 2000-11-15



                                                                    OMB APPROVAL
                                                            OMB NUMBER 3235-0058
                                                           EXPIRES: MAY 31, 1997
                                                        Estimated average burden
                                                        hour per response...2.50

                                                                 SEC FILE NUMBER
                                                                          1-7948

                                                                    CUSIP NUMBER

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING


(Check One): __ Form 10-K __  Form 20-F __  Form 11-K  X Form 10Q  __ Form N-SAR

     For Period Ended: September 30, 2000
     [ ] Transition Report on Form 10-K
     [ ]Transition Report on Form 20-F
     [ ] Transition Report on Form 11-K
     [ ] Transition Report on Form 10-Q
     [ ] Transition Report on Form N-SAR
     For the Transition Period Ended:_________________________________________

  Read Instruction (on back page) Before Preparing Form. Please Print or Type.
  ----------------------------------------------------------------------------
Nothing  in this  form  shall be  construed  to imply  that the  Commission  has
verified any information contained herein.

If the notification relates to a portion of the filing check above, identify the
Item(s) to which the notification relates:

PART I -- REGISTRANT INFORMATION
     CELLMETRIX, INC.
Full Name of Registrant

     BCAM INTERNATIONAL, INC.
Former Name if Applicable

     1800 Walt Whitman Road
Address of Principal Executive Office (Street and Number)

     Melville, NY 11747
City, State and Zip Code

PART II -- RULES 12b-25(b) and (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate).

     (a)  The reasons  described in  reasonable  detail in Part III of this form
          could not be eliminated without unreasonable effort or expense;

     (b)  The subject annual report,  semi-annual  report,  transition report on
          Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,  will be
          filed on or before the fifteenth calendar day following the prescribed
          due date; or the subject quarterly report of transition report on Form
          10-Q, or portion thereof will be filed on or before the fifth calendar
          day following the prescribed due date; and

     (c)  The accountant's statement or other exhibit required by Rule 12b-25(c)
          has been attached if applicable.

PART III - NARRATIVE

State below in reasonable  detail the reasons why Forms 10-K,  20-F, 11-K, 10-Q,
N-SAR, or the transition  report or portion  thereof,  could not be filed within
the prescribed time period.

     The Company  currently  does not have a Chief  Financial  Officer which has
     delayed  the  completion  of its  financial  statements.  Because  of  this
     vacancy,  management needs an additional  period of five days from the date
     hereof to finalize the  financial  statements  and file Form 10-QSB for the
     quarter ended September 30, 2000.

PART IV - OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification

         Michael Recca                  (914)                      712-0620
         -------------                  -----                      --------
             (Name)                  (Area Code)              (Telephone Number)

(2)  Have all other periodic  reports  required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter  period that the
     registrant  was required to file such  report(s)  been filed?  If answer is
     not, identify report(s),                                       X Yes   __No

     ---------------------------------------------------------------------------

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding  period for the last fiscal year will be reflected by the
     earnings  statements  to be  included  in the  subject  report  or  portion
     thereof?                                                       X Yes   __No

     If so, attach an explanation of the anticipated  change,  both  narratively
     and quantitatively, and, if appropriate, state the reasons why a reasonable
     estimate of the results cannot be made. (See attached Exhibit IV-3)


                            BCAM INTERNATIONAL, INC.
                  (Name of Registrant as Specified in Charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
hereunto duly authorized.


Date:  November 14, 2000                      By: /s/
                                                 -------------------------------
                                                 Michael Recca, Chairman of the
                                                   Board of Directors


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission